TY - JOUR
T1 - Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1
AU - Koya, Junji
AU - Saito, Yuki
AU - Kameda, Takuro
AU - Kogure, Yasunori
AU - Yuasa, Mitsuhiro
AU - Nagasaki, Joji
AU - McClure, Marni B.
AU - Shingaki, Sumito
AU - Tabata, Mariko
AU - Tahira, Yuki
AU - Akizuki, Keiichi
AU - Kamiunten, Ayako
AU - Sekine, Masaaki
AU - Shide, Kotaro
AU - Kubuki, Yoko
AU - Hidaka, Tomonori
AU - Kitanaka, Akira
AU - Nakano, Nobuaki
AU - Utsunomiya, Atae
AU - Togashi, Yosuke
AU - Ogawa, Seishi
AU - Shimoda, Kazuya
AU - Kataoka, Keisuke
N1 - Funding Information:
This work was supported by AMED [JP20wm0325013 (K. Kataoka), JP19ck0106261 (K. Kataoka), JP19ck0106254 (K. Shimoda), JP20ck0106542 (K. Kataoka), JP20ck0106538 (K. Shimoda), and JP20cm0106575 (K. Kataoka)], Japan Society for the Promotion of Science (JSPS) KAKENHI (19K22573 to K. Kataoka), National Cancer Center Research and Development Funds (31-A-4 to K. Kataoka), Takeda Science Foundation (K. Kataoka), Japan Leukemia Research Fund (K. Kataoka), and The Naito Foundation (K. Kataoka). The authors thank Y. Hokama, F. Ueki, and Y. Ito for technical assistance. The sequencing resources for scTCR/BCR-seq were provided by Fundamental Innovative Oncology Core at the National Cancer Center. The supercomputing resources were provided by the Human Genome Center, the Institute of Medical Science, The University of Tokyo.
Funding Information:
N. Nakano reports personal fees from Novartis Pharma, Takeda Pharmaceutical, Kyowa Kirin, Celgene, Eisai, Nippon Shinyaku, Astellas Pharma, Bristol Myers Squibb, MSD, Otsuka Pharmaceutical, Asahi Kasei Medical, Chugai Pharmaceutical, and JIMRO outside the submitted work. A. Utsunomiya reports personal fees from Novartis Pharma, Kyowa Kirin, Daiichi Sankyo, Bristol Myers Squibb, Celgene, Pfizer, Minophagen Pharmaceutical, Janssen Pharmaceutical, HUYA Japan, JIMRO, Meiji Seika Pharma, and Otsuka Medical Devices outside the submitted work. Y. Togashi reports grants and personal fees from Ono Pharmaceutical and Bristol Myers Squibb; personal fees from Chugai Pharmaceutical and MSD; and grants from KOTAI Biotechnologies and Daiichi Sankyo outside the submitted work. S. Ogawa reports a patent for P6810396 licensed and with royalties paid from Asahi Genomics. K. Kataoka reports grants from AMED, Japan Society for the Promotion of Science, National Cancer Center Research and Development Funds, Takeda Science Foundation, Japan Leukemia Research Fund, and The Naito Foundation during the conduct of the study; grants, personal fees, and nonfinancial support from Otsuka Pharmaceutical, grants from Chordia
Publisher Copyright:
©2021 The Authors; Published by the American Association for Cancer Research.
PY - 2021/9/1
Y1 - 2021/9/1
N2 - Premalignant clonal expansion of human T-cell leukemia virus type-1 (HTLV-1)–abstRact infected cells occurs before viral carcinogenesis. Here we characterize premalignant cells and the multicellular ecosystem in HTLV-1 infection with and without adult T-cell leukemia/ lymphoma (ATL) by genome sequencing and single-cell simultaneous transcriptome and T/B-cell receptor sequencing with surface protein analysis. We distinguish malignant phenotypes caused by HTLV-1 infection and leukemogenesis and dissect clonal evolution of malignant cells with different clinical behavior. Within HTLV-1–infected cells, a regulatory T-cell phenotype associates with premalignant clonal expansion. We also delineate differences between virus- and tumor-related changes in the nonmalignant hematopoietic pool, including tumor-specific myeloid propagation. In a newly generated conditional knockout mouse model recapitulating T-cell–restricted CD274 (encoding PD-L1) gene lesions found in ATL, we demonstrate that PD-L1 overexpressed by T cells is transferred to surrounding cells, leading to their PD-L1 upregulation. Our findings provide insights into clonal evolution and immune landscape of multistep virus carcinogenesis.
AB - Premalignant clonal expansion of human T-cell leukemia virus type-1 (HTLV-1)–abstRact infected cells occurs before viral carcinogenesis. Here we characterize premalignant cells and the multicellular ecosystem in HTLV-1 infection with and without adult T-cell leukemia/ lymphoma (ATL) by genome sequencing and single-cell simultaneous transcriptome and T/B-cell receptor sequencing with surface protein analysis. We distinguish malignant phenotypes caused by HTLV-1 infection and leukemogenesis and dissect clonal evolution of malignant cells with different clinical behavior. Within HTLV-1–infected cells, a regulatory T-cell phenotype associates with premalignant clonal expansion. We also delineate differences between virus- and tumor-related changes in the nonmalignant hematopoietic pool, including tumor-specific myeloid propagation. In a newly generated conditional knockout mouse model recapitulating T-cell–restricted CD274 (encoding PD-L1) gene lesions found in ATL, we demonstrate that PD-L1 overexpressed by T cells is transferred to surrounding cells, leading to their PD-L1 upregulation. Our findings provide insights into clonal evolution and immune landscape of multistep virus carcinogenesis.
UR - http://www.scopus.com/inward/record.url?scp=85140341556&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140341556&partnerID=8YFLogxK
U2 - 10.1158/2643-3230.BCD-21-0044
DO - 10.1158/2643-3230.BCD-21-0044
M3 - Article
C2 - 34661162
AN - SCOPUS:85140341556
SN - 2643-3230
VL - 2
SP - 450
EP - 467
JO - Blood cancer discovery
JF - Blood cancer discovery
IS - 5
ER -